Elsevier

Neuroscience Letters

Volume 483, Issue 3, 15 October 2010, Pages 167-172
Neuroscience Letters

Altered GABAA receptor subunit expression and pharmacology in human Angelman syndrome cortex

https://doi.org/10.1016/j.neulet.2010.08.001Get rights and content

Abstract

The neurodevelopmental disorder Angelman syndrome is most frequently caused by deletion of the maternally derived chromosome 15q11-q13 region, which includes not only the causative UBE3A gene, but also the β353 GABAA receptor subunit gene cluster. GABAergic dysfunction has been hypothesized to contribute to the occurrence of epilepsy and cognitive and behavioral impairments in this condition. In the present study, analysis of GABAA receptor subunit expression and pharmacology was performed in cerebral cortex from four subjects with Angelman syndrome and compared to that from control tissue. The membrane fraction of frozen postmortem neocortical tissue was isolated and subjected to quantitative Western blot analysis. The ratios of β32 and α51 subunit protein expression in Angelman syndrome cortex were significantly decreased when compared with controls. An additional membrane fraction was injected into Xenopus oocytes, resulting in incorporation of the brain membrane vesicles with their associated receptors into the oocyte cellular membrane. Two-electrode voltage-clamp analysis of GABAA receptor currents was then performed. Studies of GABAA receptor pharmacology in Angelman syndrome cortex revealed increased current enhancement by the α1-selective benzodiazepine-site agonist zolpidem and by the barbiturate phenobarbital, while sensitivity to current inhibition by zinc was decreased. GABAA receptor affinity and modulation by neurosteroids were unchanged. This shift in GABAA receptor subunit expression and pharmacology in Angelman syndrome is consistent with impaired extrasynaptic but intact to augmented synaptic cortical GABAergic inhibition, which could contribute to the epileptic, behavioral, and cognitive phenotypes of the disorder.

References (34)

  • E.C Burgard et al.

    Properties of recombinant gamma-aminobutyric acid A receptor isoforms containing the alpha 5 subunit subtype

    Mol. Pharmacol.

    (1996)
  • T.M. DeLorey et al.

    Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome

    J. Neurosci.

    (1998)
  • R.L. Fradley et al.

    Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands

    J. Psychopharmacol.

    (2007)
  • K.L. Hadingham et al.

    Role of the beta subunit in determining the pharmacology of human gamma-aminobutyric acid type A receptors

    Mol. Pharmacol.

    (1993)
  • A. Handforth et al.

    Pharmacologic evidence for abnormal thalamocortical functioning in GABA receptor beta3 subunit-deficient mice, a model of Angelman syndrome

    Epilepsia

    (2005)
  • A. Hogart et al.

    15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders

    Hum. Mol. Genet.

    (2007)
  • I.E. Holopainen et al.

    Decreased binding of [11C]flumazenil in Angelman syndrome patients with GABA(A) receptor beta3 subunit deletions

    Ann. Neurol.

    (2001)
  • Cited by (29)

    • Out of thin air: Hyperventilation-triggered seizures

      2019, Brain Research
      Citation Excerpt :

      Finally, mutations in the β3 subunit of the GABAA receptor are also associated with SWDs. And again, the emerging picture indicates that β3 subunit mutations reduce the number of functional GABAA receptors and, generally, reduce inhibition (Jones-Davis and Macdonald, 2003; Huntsman et al., 1999; Roden et al., 2010). In contrast to the aforementioned, loss-of-function mutations in the GABAA receptor, T-Type Ca2+ channel mutations associated with absence epilepsy lead to a gain of function.

    • Effects of the synthetic neurosteroid ganaxolone on seizure activity and behavioral deficits in an Angelman syndrome mouse model

      2017, Neuropharmacology
      Citation Excerpt :

      Consequently, clinical trials are warranted. In addition, our results are consistent with other work (Roden et al., 2010) suggesting that positive modulators of extrasynaptic GABAA receptors might in general provide unique symptomatic benefits in AS. Investigation of other extrasynaptic GABAA receptors’ active agents including gaboxadol will be of interest.

    • Xenopus laevis

      2017, Models of Seizures and Epilepsy: Second Edition
    View all citing articles on Scopus
    View full text